HK1028877A1 - Self-emulsifying formulation for lipophilic compounds - Google Patents

Self-emulsifying formulation for lipophilic compounds

Info

Publication number
HK1028877A1
HK1028877A1 HK00108278A HK00108278A HK1028877A1 HK 1028877 A1 HK1028877 A1 HK 1028877A1 HK 00108278 A HK00108278 A HK 00108278A HK 00108278 A HK00108278 A HK 00108278A HK 1028877 A1 HK1028877 A1 HK 1028877A1
Authority
HK
Hong Kong
Prior art keywords
diglyceride
monoglyceride
self
lipophilic compounds
emulsifying formulation
Prior art date
Application number
HK00108278A
Other languages
English (en)
Inventor
Walter Morozowich
Ping Gao
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of HK1028877A1 publication Critical patent/HK1028877A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
HK00108278A 1997-07-29 2000-12-21 Self-emulsifying formulation for lipophilic compounds HK1028877A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5407897P 1997-07-29 1997-07-29
PCT/US1998/014816 WO1999006043A1 (en) 1997-07-29 1998-07-27 Self-emulsifying formulation for lipophilic compounds

Publications (1)

Publication Number Publication Date
HK1028877A1 true HK1028877A1 (en) 2001-03-09

Family

ID=21988649

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00108278A HK1028877A1 (en) 1997-07-29 2000-12-21 Self-emulsifying formulation for lipophilic compounds

Country Status (23)

Country Link
US (2) US6531139B1 (xx)
EP (1) EP0999838B1 (xx)
JP (1) JP5005847B2 (xx)
KR (1) KR100509130B1 (xx)
CN (1) CN1113650C (xx)
AT (1) ATE215370T1 (xx)
AU (1) AU728695B2 (xx)
BR (1) BR9810866B1 (xx)
CA (1) CA2294032A1 (xx)
DE (1) DE69804624T2 (xx)
DK (1) DK0999838T3 (xx)
ES (1) ES2174462T3 (xx)
FI (1) FI20000171A (xx)
HK (1) HK1028877A1 (xx)
HU (1) HU225160B1 (xx)
NO (1) NO323773B1 (xx)
NZ (1) NZ502567A (xx)
PL (1) PL192080B1 (xx)
PT (1) PT999838E (xx)
RU (1) RU2203648C2 (xx)
SI (1) SI0999838T1 (xx)
SK (1) SK284579B6 (xx)
WO (1) WO1999006043A1 (xx)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2219895T3 (es) * 1997-07-29 2004-12-01 PHARMACIA & UPJOHN COMPANY Formulacion autoemulsionante para compuestos lipofilos.
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
GB9903547D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ATE287714T1 (de) * 1999-03-31 2005-02-15 Upjohn Co Pharmazeutische emulsionen für retroviral- protease hemmende verbindungen
US6956048B2 (en) 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
FR2805761B1 (fr) * 2000-03-02 2002-08-30 Mainelab Nanocapsules lipidiques, procede de preparation et utilisation comme medicament
KR20010100194A (ko) * 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
US6623765B1 (en) * 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
EE200300201A (et) * 2000-10-31 2003-08-15 Boehringer Ingelheim Pharmaceuticals, Inc. Püranoonsete proteaasi inhibiitorite iseemulgeeruva kompositsiooni oraalne doos
KR20020066778A (ko) * 2001-02-13 2002-08-21 한국과학기술연구원 체내 난흡수 물질의 흡수촉진용 조성물과 제형 및 그의제조방법
US6680470B1 (en) * 2001-11-14 2004-01-20 Dicon Fiberoptics, Inc. Interleaver with thermal and chromatic dispersion compensation
CA2466851C (en) * 2001-11-26 2012-09-11 Supergen, Inc. Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
US20030191093A1 (en) * 2001-12-03 2003-10-09 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20030165545A1 (en) * 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20030199584A1 (en) * 2002-04-11 2003-10-23 Ahluwalia Gurpreet S. Reduction of hair growth
US7182950B2 (en) 2002-06-12 2007-02-27 Nutralease Ltd. Nano-sized self-assembled liquid dilutable vehicles
KR100533458B1 (ko) * 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
US20050196370A1 (en) * 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
US20060251685A1 (en) * 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
GB0402679D0 (en) * 2004-02-06 2004-03-10 Novartis Ag Organic compounds
KR20050081092A (ko) * 2004-02-12 2005-08-18 한국과학기술연구원 생체적합성 친수성 고분자를 포함하는 콜로이드계 조성물,제형 및 이들의 제조 방법
EP1966192B1 (en) * 2005-12-01 2012-10-17 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
WO2008058234A2 (en) * 2006-11-08 2008-05-15 Memory Pharmaceuticals Corporation Pharmaceutical formulations for 1,4-dihyrdropyridine compounds having improved solubility
CN101627031A (zh) * 2007-03-09 2010-01-13 诺瓦提斯公司 3-(1h-吲哚-3-基)-4-[2-(4-甲基-哌嗪-1-基)-喹唑啉-4-基]-吡咯-2,5-二酮的盐
JP2011504162A (ja) * 2007-05-23 2011-02-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 経口投与用チプラナビルの自己乳化型製剤
HU227873B1 (hu) * 2007-06-18 2012-05-29 Biogreen As Növényicsíra-alapú emulziók, eljárás az elõállításukra és alkalmazásuk
AU2008269179A1 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without Tween 80
KR20100121505A (ko) 2008-03-07 2010-11-17 싸이도우스 엘엘씨. 플배스트랜 제제
US8861813B2 (en) * 2008-03-13 2014-10-14 Mallinckrodt Llc Multi-function, foot-activated controller for imaging system
US20110275717A1 (en) * 2008-11-28 2011-11-10 Advance Holdings Limited Pharmaceutical formulation comprising diclofenac
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
PT2451438E (pt) 2009-07-07 2014-03-26 Boehringer Ingelheim Int Composição farmacêutica para um inibidor de protease viral da hepatite c
WO2011047259A1 (en) 2009-10-16 2011-04-21 Glaxosmithkline Llc Compositions
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
KR101752944B1 (ko) 2010-05-03 2017-07-03 테이코쿠 팔마 유에스에이, 인코포레이티드 비수성의 탁산 프로에멀젼 제제, 및 그의 제조 및 사용 방법
WO2012010942A2 (en) * 2010-07-22 2012-01-26 Lupin Limited Novel pharmaceutical composition(s) of hiv protease inhibitor(s)
US9468638B2 (en) 2010-09-24 2016-10-18 Texas Southern University Itraconazole formulations
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US10711238B2 (en) 2012-10-02 2020-07-14 Repligen Corporation Method for proliferation of cells within a bioreactor using a disposable pumphead and filter assembly
WO2014128564A2 (en) 2013-02-21 2014-08-28 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
EP3248599B1 (en) * 2015-01-21 2022-07-06 Mochida Pharmaceutical Co., Ltd. Omega-3 fatty acid self-emulsifying composition
CN117547528A (zh) 2015-05-28 2024-02-13 瑞迪博士实验室有限公司 用于治疗疼痛的塞来昔布口服组合物
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
JP2020503269A (ja) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド 経口ウンデカン酸テストステロン療法
TWI676824B (zh) 2019-01-09 2019-11-11 友達光電股份有限公司 顯示裝置及顯示方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230702A (en) * 1978-01-09 1980-10-28 Kali-Chemie Pharma Gmbh Readily enterally absorbable pharmaceutical compositions of per se poorly enterally absorbable pharmacologically active agents
JPS5618914A (en) * 1979-07-25 1981-02-23 Eisai Co Ltd Ubidecarenone composition having good absorbability
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
JPH0629180B2 (ja) * 1986-06-16 1994-04-20 エーザイ株式会社 吸収性の改良されたメナテトレノン含有組成物
DE3629386A1 (de) * 1986-08-29 1988-03-03 Scherer Gmbh R P Gelatinekapseln und verfahren zu ihrer herstellung
ATE77559T1 (de) * 1986-11-14 1992-07-15 Theratech Inc Erhoehung des penetrationsvermoegens mittels eines aus die zellhuelle veraendernden substanzen und kurzkettigen alkoholen bestehenden binaeren systems.
JP2632010B2 (ja) * 1988-01-29 1997-07-16 三共株式会社 シクロスポリン製剤
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
IL102236A0 (en) * 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
PT589843E (pt) * 1992-09-25 2002-04-29 Novartis Ag Composicoes farmaceuticas contendo ciclosporinas
WO1994008603A1 (en) * 1992-10-16 1994-04-28 Smithkline Beecham Corporation Compositions
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
SK282121B6 (sk) 1995-06-06 2001-11-06 F. Hoffmann-La Roche Ag Farmaceutický prostriedok obsahujúci terapeuticky účinné množstvo inhibítora proteinázy
DE19537012A1 (de) * 1995-10-04 1997-04-10 Dietl Hans Cyclosporin(e) enhaltende pharmazeutische Zubereitung zur oralen Applikation und Verfahren zu ihrer Herstellung
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
ES2219895T3 (es) * 1997-07-29 2004-12-01 PHARMACIA & UPJOHN COMPANY Formulacion autoemulsionante para compuestos lipofilos.

Also Published As

Publication number Publication date
SK182000A3 (en) 2000-12-11
DE69804624D1 (de) 2002-05-08
HUP0003292A3 (en) 2002-02-28
NO20000465D0 (no) 2000-01-28
ATE215370T1 (de) 2002-04-15
BR9810866B1 (pt) 2010-07-13
SI0999838T1 (en) 2002-08-31
HUP0003292A1 (hu) 2002-01-28
PT999838E (pt) 2002-07-31
AU728695B2 (en) 2001-01-18
BR9810866A (pt) 2000-09-26
US6121313A (en) 2000-09-19
EP0999838A1 (en) 2000-05-17
JP2002510329A (ja) 2002-04-02
ES2174462T3 (es) 2002-11-01
AU8573798A (en) 1999-02-22
EP0999838B1 (en) 2002-04-03
PL338334A1 (en) 2000-10-23
KR100509130B1 (ko) 2005-08-18
NO323773B1 (no) 2007-07-02
CA2294032A1 (en) 1999-02-11
RU2203648C2 (ru) 2003-05-10
DE69804624T2 (de) 2002-09-19
HU225160B1 (en) 2006-07-28
NZ502567A (en) 2002-03-28
WO1999006043A1 (en) 1999-02-11
FI20000171A (fi) 2000-01-28
KR20010022364A (ko) 2001-03-15
JP5005847B2 (ja) 2012-08-22
CN1113650C (zh) 2003-07-09
US6531139B1 (en) 2003-03-11
PL192080B1 (pl) 2006-08-31
SK284579B6 (sk) 2005-07-01
DK0999838T3 (da) 2002-07-08
CN1261797A (zh) 2000-08-02
NO20000465L (no) 2000-03-28

Similar Documents

Publication Publication Date Title
HK1028877A1 (en) Self-emulsifying formulation for lipophilic compounds
CA2294031A1 (en) SELF-EMULSIFYING FORMULATION FOR LIPOPHILIC COMPOUNDS
BR9810729B1 (pt) composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsificante.
DK1173153T3 (da) Orale farmaceutiske præparater, som indeholder langkædede triglycerider og lipofile overfladeaktive midler
CA2294337A1 (en) Preparation of pharmaceutical compositions
CA2285242A1 (en) Mixture of primary fatty acids obtained from sugar cane wax
ES2141049A1 (es) Formulaciones farmaceuticas en aerosol que contienen trigliceridos de cadena media como surfactantes.
MY130474A (en) Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150727